Navigation Links
SuperGen Reports 2007 Fourth Quarter and Annual Financial Results
Date:3/3/2008

Company Achieves 2007 Net Income of $13.1 Million

DUBLIN, Calif., March 3 /PRNewswire-FirstCall/ -- SuperGen Inc., (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today reported financial results for the fourth quarter and year ended December 31, 2007.

The Company reported net income for the 2007 fourth quarter of $5.1 million, or $0.09 per fully diluted share, compared with a net loss of $6.3 million, or $0.11 per fully diluted share, for the same prior year period. The Company reported net income for the year ended December 31, 2007 of $13.1 million, or $0.23 per fully diluted share, compared with a net loss of $16.5 million, or $0.31 per fully diluted share, for the same prior year period.

Highlights for 2007 include:

-- Dacogen royalty revenue was $22.3 million compared to $3.4 million for

2006.

-- A major contributor to net income during 2007 was the gain on

disposition of non-core assets including the sale of worldwide rights

for Nipent(R) (pentostatin for injection) and Surface Safe(R),

resulting in a reported gain on sale of products of $33.7 million.

-- The Company closed the year with unrestricted cash, cash equivalents,

and marketable securities totaling approximately $91 million.

"SuperGen has again achieved several significant milestones during 2007 including the start of Phase 1 and Phase 1b clinical trials of MP470, a novel, oral, multi-targeted tyrosine kinase inhibitor (TKI)," said Dr. James Manuso, President and Chief Executive Officer. "We entered 2008 with a strong financial position. Our lice>

Ended Ended

December 31, December 31,

2007 2006 2007 2006

(Unaudited) (Unaudited)

Revenues:

Net product revenue $- $467 $621 $9,563

Development and license revenue

from MGI PHARMA - 29 - 25,093

Royalty revenue 7,797 2,384 22,333 3,427

Total revenues 7,797 2,880 22,954 38,083

Costs and operating expenses:

Cost of product revenue - 126 221 2,003

Research and development 6,237 5,035 23,423 16,544

Selling, general, and

administrative 3,175 5,402 13,520 24,714

Acquired in-process research and

development - - 9,967 16,318

Gain on sale of products (6,000) - (33,677) -

Total costs and operating expenses 3,412 10,563 13,454 59,579

Income (loss) from operations 4,385 (7,683) 9,500 (21,496)

Interest income 990 952 4,017 2,746

Gain on disposition of investment

in AVI BioPharma stock

resulting from exercise of warrant - - - 780

Other income (expense) (59) 241 (25) 241

Change in valuation of derivatives - 490 - 1,817

Income (loss) before income tax

provision 5,316 (6,000) 13,492 (15,912)

Income tax provision (175) (323) (411) (575)

Net income (loss) $5,141 $(6,323) $13,081 $(16,487)

Net income (loss) per common share:

Basic $0.09 $(0.11) $0.23 $(0.31)

Diluted $0.09 $(0.11) $0.23 $(0.31)

Weighted average shares used in net

income (loss) per common

share calculation:

Basic 57,499 55,164 56,868 53,439

Diluted 57,661 55,164 57,301 53,439

SUPERGEN, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)

December 31,

2007 2006

(Unaudited)

ASSETS

Current assets:

Cash and cash equivalents $78,055 $67,704

Marketable securities 9,375 -

Accounts receivable, net 71 489

Development revenue receivable

from MGI PHARMA - 29

Accounts receivable from Mayne

Pharma 58 1,502

Inventories, net - 223

Prepaid distribution and

marketing rights - 630

Prepaid expenses and other

current assets 728 1,111

Total current assets 88,287 71,688

Marketable securities, non-current 3,419 179

Investment in stock of related

parties - 659

Property, plant and equipment, net 4,435 3,752

Goodwill 731 731

Other intangibles, net 532 958

Restricted cash and investments,

non-current 2,536 10,043

Other assets 508 36

Total assets $100,448 $88,046

LIABILITIES & STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable $2,327 $3,864

Accrued liabilities 687 1,338

Payable to AVI BioPharma 565 565

Deferred gain on sale of

products to Mayne Pharma 600 11,754

Deferred revenue - 459

Accrued payroll and employee

benefits 2,782 3,296

Total current liabilities 6,961 21,276

Deferred rent 832 938

Total liabilities 7,793 22,214

Total stockholders' equity 92,655 65,832

Total liabilities and

stockholders' equity $100,448 $88,046

nse agreement with MGI PHARMA, now an Eisai company, is expected to yield increasing royalty revenues. Our financial position and revenue prospects will be used to fund the development of a rich pipeline that will ultimately enhance overall stockholder value."

2007 Fourth Quarter Results

Total revenues for the 2007 fourth quarter were $7.8 million, compared with $2.9 million for the same prior year period. Royalty revenue for the 2007 fourth quarter was $7.8 million, compared with $2.4 million for the same prior year period. Royalty revenue is earned pursuant to the license agreement entered into with MGI PHARMA during 2004, which granted MGI PHARMA exclusive rights to the development, manufacture, commercialization and distribution of Dacogen(R) (decitabine) for Injection. The Company recognizes royalty revenue on a cash basis when it is received. There was no net product revenue for the 2007 fourth quarter compared with net product revenue of $467,000 for the same prior year period. The decrease in net product revenue during the 2007 fourth quarter was primarily due to the sale of the Company's worldwide rights for Nipent and Surface Safe to Mayne Pharma (acquired by Hospira, Inc. in February 2007).

Excluding the gain on sale of products, total costs and operating expenses for the 2007 fourth quarter were $9.4 million, compared with $10.6 million for the same prior year period. The primary reasons for the decrease in total costs and operating expenses for the 2007 fourth quarter were reductions in cost of product revenue and sales and marketing expenses resulting from the sale of the Company's worldwide rights for Nipent and Surface Safe to Mayne Pharma, offset in part by higher research and development costs related to product development activities and an increase in the non-cash charge for stock-based compensation expense. Included in the gain on sale of products for the 2007 fourth quarter was the receipt of additional milestones earned on the sale of products to Mayne Pharma. There were no similar milestone payments for the same prior year period.

The Company reported net income for the 2007 fourth quarter of $5.1 million, or $0.09 per fully diluted share, compared with a net loss of $6.3 million, or $0.11 per fully diluted share, for the same prior year period. Included in net income for the 2007 fourth quarter is the gain on sale of products for additional milestone payments earned of $6.0 million, a non-cash charge of $1.1 million for stock-based compensation expense and an income tax provision of $175,000 resulting primarily from the tax impact of recognizing various milestone payments received from the sale of products to Mayne Pharma. Included in the 2006 fourth quarter net loss is a non-cash gain for a change in valuation of derivatives of $490,000. There was no similar non-cash gain during the 2007 fourth quarter because the related derivatives expired at the end of 2006.

2007 Year-End Financial Results

Total revenues for 2007 were $23.0 million, compared with $38.1 million for the same prior year period. Royalty revenue for 2007 was $22.3 million, compared with $3.4 million for the same prior year period. Royalty revenue is earned pursuant to the license agreement previously entered into with MGI PHARMA. The Company recognizes royalty revenue on a cash basis when it is received. Total revenues for 2006 included $25.1 million of primarily milestone payments included in development and license revenue pursuant to the license agreement with MGI PHARMA. There was no similar development and license revenue for 2007. Net product revenue for 2007 was $621,000, compared to $9.6 million for the same prior year period. The reduction in net product revenue for 2007 was primarily due to the sale of the Company's worldwide rights for Nipent and Surface Safe to Mayne Pharma.

Excluding the gain on sale of products, total costs and operating expenses for 2007 were $47.1 million, compared with $59.6 million for the same prior year period. The primary reasons for the decrease in total costs and operating expenses for 2007 were a lower net non-cash operating charge relating to acquired in-process research and development associated with the acquisition of Montigen Pharmaceuticals and reductions in the cost of product revenue and sales and marketing expenses resulting primarily from the sale of the Company's worldwide rights for Nipent and Surface Safe offset in part by higher research and development costs related to increased product development activities and an increase in the non-cash charge for stock-based compensation expense. Included in the gain on sale of products for 2007 was the recognition of the deferred gain and additional gains recognized on the sale of products to Mayne Pharma as well as the recognition of gains on the sale of other products to Intas Pharmaceuticals.

The Company reported net income for 2007 of $13.1 million, or $0.23 per fully diluted share, compared with a net loss of $16.5 million, or $0.31 per fully diluted share, for the same prior year period. Included in net income for 2007 is a gain on sale of products of $33.7 million offset in part by a non-cash operating charge relating to acquired in-process research and development of approximately $10.0 million, a non-cash charge of $4.3 million for stock-based compensation expense and an income tax provision of $411,000 resulting primarily from the tax impact of recognizing various milestone payments received from the sale of products to third parties. Included in the net loss for 2006 was a non-cash gain for a change in valuation of derivatives of $1.8 million. There was no similar non-cash gain during 2007 because the related derivatives expired at the end of 2006.

As of December 31, 2007, the Company had approximately $91 million in unrestricted cash, cash equivalents and marketable securities.

2008 Financial Guidance

The Company expects to report royalty revenue for 2008 in a range from $32 million to $35 million. The Company's royalty revenue is initially based on the annual end user guidance of approximately $157 million for 2008 provided by Eisai Co., Ltd. (which acquired MGI PHARMA in January 2008) in its quarterly conference call in early February 2008. The Company recognizes royalty revenue on a cash basis when it is received. The Company also expects to record additional milestones that relate to the prior sale of products to Mayne Pharma that are estimated to range from $1.6 million to $2.6 million. No other cash flows resulting from business development transactions are currently reflected in the 2008 financial guidance. Research and development expenses for 2008 are expected to total approximately $34 million to $36 million with the growth over 2007 influenced by increasing costs related to clinical trial programs such as MP470, ongoing product development efforts with the product pipeline and increasing investment in the discovery, pre- clinical, regulatory and clinical areas of the Company. The Company expects to record a non-cash charge during 2008 of approximately $5.2 million for acquired in-process research and development which relates to a milestone payment to the former Montigen stockholders for the filing of a second Investigational New Drug application with the Food and Drug Administration. Selling, general and administrative expenses for 2008 are expected to total approximately $14 million. Included in the 2008 total operating expenses are non-cash stock-based compensation expenses of approximately $4.3 million. Based on the elements of the 2008 financial guidance the Company is estimating a loss from operations in a range from $18 million to $20 million. The Company expects average shares outstanding for 2008 will be approximately 58 million common shares.

Corporate News

October 2007:

-- As part of a series of presentations at the 2007 AACR-NCI-EORTC

International Conference, the Company announced the following: MP470, a

clinical-stage multi-targeted tyrosine kinase inhibitor, demonstrates

preclinical synergy with DNA damaging agents (Poster A173, Abstract

1026); S110, a decitabine-derived DNA demethylating agent, shows

improved pre-clinical activity due to increased drug delivery and

stability (Poster 140, Abstract 1038); and, the proprietary CLIMB(TM)

technology was successful in the lead development and design of small

molecule JAK2 and Pim kinase inhibitors (Posters C200, Abstract 907 and

C208, Abstract 985). Also, Dr. Peter A. Jones, Director of USC's Norris

Cancer Center, further discussed S110 in a plenary session on cancer

epigenetics.

-- The Company announced during an oral presentation at the American

Society for Therapeutic Radiology and Oncology's 49th Annual Meeting in

Los Angeles that MP470, a clinical-stage multi-targeted tyrosine kinase

inhibitor, is cytotoxic to glioblastoma multiforme cell lines (Abstract

178). Activity was also demonstrated in vivo in a glioblastoma

multiforme xenograft model. Evidence presented suggests that MP470

inhibits DNA damage repair through suppression of a critical DNA repair

protein, Rad51. Dr. James Welsh of the University of Arizona, who

conducted these pre-clinical studies, also revealed that the pre-

clinical activity of MP470 against glioblastoma multiforme cells is

synergistic with radiation.

December 2007:

-- As part of a series of presentations at the American Society of

Hematology's 49th Annual Meeting, the Company described how its

proprietary CLIMB technology was used in lead development and design of

small molecule Pim kinase inhibitors (Poster 845, Abstract 2655) and

how its novel decitabine dinucleotide compound, S110, activates an

important fetal hemoglobin biomarker in baboons, confirming the

product's ability to activate a specific silenced gene (Abstract 571).

An oral presentation by Donald Lavelle, Ph.D., of the University of

Illinois at Chicago, provided evidence that S110 increases fetal

hemoglobin and decreases DNA methylation in non-human primates and

cultured human erythroid progenitor cells (Poster 779). Finally the

prevention of cancer cell proliferation in non-clinical models, by the

Company's lead JAK2 kinase inhibitors was presented (Abstract 3560).

-- The Company announced that investigators dosed the first patient in a

multi-arm Phase 1b clinical trial of MP470, a novel, oral, multi-

targeted tyrosine kinase inhibitor (TKI). The trial will evaluate MP470

in combination with several standard of care chemotherapy regimens,

including carboplatin/paclitaxel, carboplatin/etoposide, docetaxel,

topotecan, and erlotinib. The trial is expected to enroll up to 105

patients at five study centers. The Phase 1b trial is an open label,

dose-escalation study designed to assess the safety and tolerability of

MP470 in combination with these standard of care chemotherapy regimens,

and to define the dose of MP470 to advance into Phase 2 combination

studies. Additionally, the Company will assess pharmacokinetic and

biomarker data from the study. The trial is open to chemotherapy naive

or treatment experienced patients with a variety of solid tumors

irrespective of previous lines of therapy.

Conference Call Information

SuperGen will host a conference call to discuss the results of the 2007 fourth quarter and annual financial results today at 1:30 p.m. PT / 4:30 p.m. ET. A live webcast of the conference call is accessible via the investor relations section of the Company's web site at http://ir.supergen.com. A webcast replay of the conference call will be available for 90 days.

About SuperGen

Based in Dublin, California, SuperGen, Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.

Forward-Looking Statements

This press release contains "forward-looking" statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and is subject to the safe harbor created thereby. The actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. These forward-looking statements include statements regarding SuperGen's expectation that it will receive the balance of the purchase price for Nipent from Mayne Pharma, expectations regarding the multi- arm Phase 1b clinical trial of MP470, a novel oral multi-targeted tyrosine kinase inhibitor (TKI), expectations about revenue, gains from sales of non- core assets and operating expenses, as well as SuperGen's expectations and successful development of all its pipeline products. Important factors that could cause actual results to differ materially from the expectations reflected in the forward-looking statements include, but are not limited to, risks and uncertainties related to the achievement of developmental milestones with respect to the compounds acquired in the Montigen acquisition, the research and development of MP470, the satisfaction of the contingencies related to the sale of the worldwide rights to Nipent and Surface Safe to Mayne Pharma, and the ability of MGI to generate global sales of Dacogen. In general, our future success is dependent upon numerous factors, including our ability to generate pre-clinical development candidates for selection into clinical testing, obtaining regulatory approval of product development programs, conducting and completing clinical trials and obtaining regulatory approval of our products and product candidates, and creating opportunities for future commercialization of compounds. Our future revenue and operating and net income or loss could be worse than anticipated if demand for our products is less than expected, or if the introduction of new products is delayed, for any reason, including regulatory delay. References made to the discussion of risk factors are detailed in the Company's filings with the Securities and Exchange Commission including reports on its most recently filed Form 10-K and Form 10-Q. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update or revise the information contained in any such forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:

Timothy L. Enns Mary M. Vegh

SuperGen, Inc. SuperGen, Inc.

SVP, Corporate Manager, Investor Relations

Communications Tel: (925) 560-2845

& Business Development

Tel: (925) 560-0100 x111

E-mail: tenns@supergen.com E-mail: mary.vegh@supergen.com

SUPERGEN, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)

Three Months Year'/>"/>

SOURCE SuperGen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. SuperGen to Announce 2007 Fourth Quarter and Fiscal Year-End Financial Results March 3, 2008
2. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
3. Dr. Audrey F. Jakubowski of SuperGen Retires as Chief Regulatory and Quality Officer
4. Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results
5. Genetic Engineering & Biotechnology News reports on advances in miRNA
6. Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 Financial Results
7. Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007
8. Cepheid Reports Fourth Quarter and Full Year 2007 Results
9. Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results
10. US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results
11. Barr Reports GAAP Earnings of $1.18 Per Share for 2007 and $0.30 Per Share for the Fourth Quarter; Adjusted Earnings Were $3.16 Per Share for 2007 and $0.79 Per Share for the Fourth Quarter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... LONDON , Feb. 9, 2016 /PRNewswire/ ... (PTP1B) Inhibitors-Pipeline Insights, 2016", report provides in ... their development activities around the Protein-Tyrosine Phosphatase ... the product profiles in various stages of ... Phase II, Phase III and Preregistration. Report ...
(Date:2/8/2016)... Should antibiotic bone cement products be used ... infection after standard total hip or knee replacement surgery? ... have been fielding a lot lately. "Antibiotic ... --> "Antibiotic Bone Cement: Fighting ... --> While there isn,t a simple answer, ECRI ...
(Date:2/8/2016)... , February 8, 2016 ... Oncology Private Limited, an innovation-driven oncology company developing ... and less toxic, today announced that chairman emeritus ... has invested in the company as part of ... round, joining existing investors Navam Capital and Aarin ...
(Date:2/8/2016)... ... 2016 , ... Thomas J. Todorow has joined the University ... Corporate Services and the Chief Financial Officer at The Children’s Hospital of Philadelphia ... Care Contracting, Supply Chain, and Investments. , Prior to joining CHOP and The ...
Breaking Biology Technology:
(Date:2/3/2016)... --> --> Fourth quarter ... up 1,187% compared with fourth quarter of 2014. Gross margin ... (loss: 30.0). Earnings per share increased to SEK 6.39 (loss: ... (neg: 74.7). , --> --> ... 2,900.5 M (233.6), up 1,142% compared with 2014. Gross margin ...
(Date:2/2/2016)... , Feb. 2, 2016  BioMEMS devices ... primarily focused on medical screening and diagnostic ... parameters. Wearable devices that facilitate and assure ... of movement are being bolstered through new ... biomedical signal acquisition coupled with wireless connectivity ...
(Date:2/2/2016)... RESTON, Va. , Feb. 2, 2016 /PRNewswire/ ... contract award from the U.S. Army Research Office ... extend the range and sensitivity of the company,s ... DoD,s Past Accounting Mission and, more generally, defense-related ... its DNA phenotyping capabilities (predicting appearance and ancestry ...
Breaking Biology News(10 mins):